According to UCLA researchers, earlier pinpointing of prostate cancer recurrence locations after radical prostatectomy means that PSMA PET/CT could help guide salvage radiotherapy, resulting in more effective treatment for many patients. {read more here}

Based on results of the phase III NETTER-1 trial, lutathera (lutetium [177Lu] oxodotreotide) has been approved by the FDA for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). {read more here}

Investigators successfully used PET/CT scanning to determine whether patients with stage IIB to IVB Hodgkin lymphoma should switch from ABVD to BEACOPP, according to updated results from the international GITIL/FIL HD 0607 trial published in the Journal of Clinical Oncology. {read more here}

Light emitted as part of traditional cancer-imaging techniques to locate metastatic tumors can also trigger light-sensitive drugs, according to a study of Washington University School of Medicine in St. Louis. {read more here}